Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GATBIO NEXT

Financiado

GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonst...

GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing GAT Biosciences (GATBIO) is a women-led Biotech SME targeting the exploitation of its proprietary GRTTM technology as a novel solution for the development and production of complex biologic drugs for biopharma and veterinary marke... ver más

31/05/2024

GAT BIOSCIENCES

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

GAT BIOSCIENCES La investigacion y desarrollo de productos basados en biotecnologia asi como la prestacion de servicios de investigacion y desarrollo de pro...

TRL 3-4 | 1M€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU ExpectedOutcome:Project results are expected to contribute to the following expected outcomes:

Innovación

Cerrada hace 2 años

0% 100% 100%

1 Participantes

GAT BIOSCIENCES

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MiStiC Microbial Synthetic in vivo Cell Therapy Systems 1M€ Cerrado

CAESAR IBD Project The CAESAR IBD Project: Developing Therapeutic Antibodies fo... 3M€ Cerrado

DISPOSITIVO BIODEGRADABLE DE LIBERACIÓN CONTR... DISPOSITIVO BIODEGRADABLE DE LIBERACIÓN CONTROLADA DE BACTER... 241K€ Rechazado

DESARROLLO DE CONOCIMIENTOS CLÍNICOS BASADOS... DESARROLLO DE CONOCIMIENTOS CLÍNICOS BASADOS EN LA APLICACIÓ... 20K€ Cerrado

PTQ-15-07555 Identificación e investigación de compuestos bioactivos inmu... 83K€ Cerrado

Bac3Gel New generation of substrates to harness the full power of mi... 2M€ Cerrado

Duración del proyecto: 12 meses Fecha Inicio: 2023-05-31
Fecha Fin: 2024-05-31

Líder del proyecto

GAT BIOSCIENCES La investigacion y desarrollo de productos basados en biotecnologia asi como la prestacion de servicios de investigacion y desarrollo de pro...

TRL 3-4 | 1M€

Presupuesto del proyecto 75K€

Descripción del proyecto GAT Biosciences (GATBIO) is a women-led Biotech SME targeting the exploitation of its proprietary GRTTM technology as a novel solution for the development and production of complex biologic drugs for biopharma and veterinary markets. Specifically, we are developing a game-changer next generation of accessible and non-invasive (oral, topic, inhaled) biopharmaceuticals through proprietary and sustainable microalgae biofactories. Our first candidate for the biopharmaceutical Market, GB-AF-004, will enter pre-clinical demonstration in 2023. GB-AF-004 is an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases and Disorders (IBDs). The term IBDs includes a range of chronic and painful autoimmune diseases affecting localy the intestine, affecting patients from their youth and throughout life and of unknown causess. More than 6 million people are affected by IBDs globally and their global treatment market is estimated by 2029 at 37 billion euros per year. GB-AF-004 has the potential to be a game-changer in the treatment of this high prevalence and chronic inflammatory intestinal diseases. GATBIO has been recently granted a Seal of Excellence from the EIC accelerator Program supporting disruptive European SMEs for their acceleration to the market. The related funding will allow us to enter the preclinical development of GB-AF-004 early in 2023. In this frame, additional support related not to scientific development per se but to reinforcing our strategic business management and vision could be key to success in our next steps and culminate GB-AF-004 out-licensing. Specifically, to access Expert mentoring and Biomed advice related to i) clinical positioning in the IBD market and ii) out-licensing strategy, would be key to success in the arrival of our 1st candidate to the regulated market and would translate into GATBIO’s consolidation and exponential growth based on innovation out-licensing.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores